Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCFA UNDECIDED ON CANCER DRUG MEDICARE COVERAGE UNDER HOME I.V

Executive Summary

HCFA UNDECIDED ON CANCER DRUG MEDICARE COVERAGE UNDER HOME I.V. provisions scheduled to begin Jan. 1, 1990. Explaining the Catastrophic Health Care Act I.V. drug provisions at a recent workshop, Thomas Hoyer of HcFA's provider services division within the Office of Coverage Policy noted that unapproved indications for cancer drugs may create a problem for HCFA. The workshop was held by the Association of Biotechnology Companies in Washington, D.C. Oct. 13. Under the law, HCfA is required to publish a list of those home I.V. drugs that it will cover. Hoyer reported that HCFA has hit a snag regarding such therapies as cancer drugs, which are often prescribed for unapproved uses. "I gather for most cancer drugs," administered by home I.V., "maybe 50% of them are for non-approved uses," Hoyer noted. "We really have, at this point, a kind of dilemma facing us . . . We're a little nervous about publishing a list of drugs that we'll pay for to be used for unapproved uses, " he stated. The Pharmaceutical Manufacturers Association has been lobbying HCFA for coverage of cancer therapies, Hoyer said. He added that the agency is "open" to outside advice and opinions on the issue. "We don't know the solution, I don't have the answer, [but] clearly we'll have to do something," he said. Hoyer added that HCFA expects to have "at least an initial idea of what we're going to do " before the end of the calendar year. Separately, HCFA's Office of Reimbursement is working on a per diem fee schedule for ancillary services associated with I.V. drug delivery under Medicare and expects to have proposed regs ready by the spring of 1989 ("The Pink Sheet" Sept. 19, p. 12). Noting that the law presents a situation where "for the first time, we have to produce a list of things we can cover," Hoyer indicated the possiblity that coverage may be limited by the difficulty of defining such a list. "It is fairly clear from the legislative history that if we don't manage to get two drugs on it, that is all we will cover," he said. Under the law, home I.V. antibiotics are automatically covered except for those HCFA specifically decides against, Hoyer pointed out. The agency must therefore prepare a list of antibiotics which it will not cover. In a separate presentation to the workshop, Prospective Payment Commission (Pro-PAC) staffer Nancy Merrick, MD, discussed HCFA's decision last spring regarding TPA. Noting that HCFA rejected ProPAC's recommendation that the prospective payment schedule hospital update factor be increased to account for the cost of the drug ("The Pink Sheet" April 4, p. 3), she maintained that TPA remains "an important issue" at ProPAC. "We are presently collecting information of costs to patients whho receive thrombolytic agents; it is on our agenda and it is a difficult issue," she said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel